Log in
Enquire now
Synklino

Synklino

Synklino is an immunotoxin drug for cytomegalovirus in transplant recipients founded in 2017 by Thomas Kledal Ph.D., MBA , Mads Jeppesen Ph.D. and Mette Rosenkilde MD, Ph.D. .

OverviewStructured DataIssuesContributors

Contents

synklino.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Technology
Technology
Biology
Biology
Biotechnology
Biotechnology
Healthcare
Healthcare
Vaccine
Vaccine
Biomedical engineering
Biomedical engineering
Organ transplantation
Organ transplantation
...
Location
‌
Lyngby, Hovedstaden, Denmark
Charlottenlund
Charlottenlund
0
B2X
B2B
B2B
CEO
Founder
‌
Thomas Kledal Ph.D., MBA
0
‌
Mads Jeppesen Ph.D.
0
‌
Mette Rosenkilde MD, Ph.D.
Pitchbook URL
pitchbook.com/profiles...433845-01
Email Address
info@synklino.com0
Phone Number
+45201216560
Full Address
Rådhusvej 13 2920 Charlottenlund Denmark0
Investors
Maj Invest
Maj Invest
0
Eir Ventures
Eir Ventures
0
Founded Date
2017
Total Funding Amount (USD)
79,700,000
Latest Funding Round Date
June 9, 2022
Business Model
Commerce
Latest Funding Type
Series A
Series A
COO
‌
Jette Wagtberg Sen
0
Country
Denmark
Denmark
0

Other attributes

Latest Funding Round Amount (USD)
31,700,000
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Synklino

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.